Daiwa Securities Group Inc. Supernus Pharmaceuticals, Inc. Transaction History
Daiwa Securities Group Inc.
- $21.6 Billion
- Q3 2024
A detailed history of Daiwa Securities Group Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 209 shares of SUPN stock, worth $7,835. This represents 0.0% of its overall portfolio holdings.
Number of Shares
209
Previous 157
33.12%
Holding current value
$7,835
Previous $4,000
75.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding SUPN
# of Institutions
279Shares Held
60.6MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$390 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$230 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$191 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$108 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$98.7 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.01B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...